Laronde’s Cagnoni to head R&D at Incyte
Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink
Pablo Cagnoni is leaving Flagship Pioneering portfolio company Laronde Inc. as CEO to join Incyte Corp. (NASDAQ:INCY) as president and head of R&D, effective June 5, while remaining a member of the circular RNA company’s board. Cagnoni, a Flagship executive partner, led Rubius Therapeutics Inc. (NASDAQ:RUBY), another Flagship play, until November, when the company announced it would explore strategic alternatives. Prior to that, he was CEO of Tizona Therapeutics Inc. and served as president of Onyx Pharmaceuticals Inc.
Flagship Executive Partner and Laronde Chairman John Mendlein will return to his role as Laronde’s interim CEO. Laronde also hired Trevor Hallam as CSO, starting May 15. Hallam was president of research and CSO at Sutro Biopharma Inc. (NASDAQ:STRO) and succeeds interim CSO Avak Kahvejian, a Laronde co-founder and Flagship Pioneering general partner who will remain a board member and adviser to the CEO and chairman...